Core Viewpoint - BioStem Technologies, Inc. is showcasing its innovative placental-derived products for chronic wound care at the Symposium for Advanced Wound Care (SAWC) Fall meeting, emphasizing collaboration with Venture Medical, LLC to enhance patient care and streamline treatment processes [1][2]. Company Overview - BioStem Technologies focuses on the development, manufacturing, and commercialization of placental-derived products aimed at advanced wound care [1][11]. - The company utilizes its proprietary BioREtain processing method, which preserves the natural properties of perinatal tissue, ensuring the integrity of amniotic tissue components critical for wound treatment [8][11]. Product Highlights - Key products include AmnioWrap2® and Vendaje AC®, which are exclusively available through Venture Medical [3]. - The BioStem-Venture collaboration aims to provide a superior allograft platform that meets the needs of both patients and healthcare providers [3]. Event Details - The SAWC Fall meeting is taking place from September 3-6 in Las Vegas, NV, serving as a significant educational forum for healthcare professionals focused on chronic wound care [1]. - A sponsored breakfast symposium titled "Navigating the Future of Wound Care" will feature discussions on clinical evidence and best practices in wound care management [4]. Research Contributions - BioStem has three clinical and scientific posters accepted for display at the symposium, contributing to the discourse on chronic wound care [5][10]. - Research topics include comparisons of processing methods for placental tissue allografts and sterilization methods for dehydrated birth tissue [6][10]. Strategic Partnership - The collaboration with Venture Medical enhances the logistics of managing patients requiring skin substitutes for chronic wound treatment, showcasing a combined value proposition [2][3][13].

Core Insights - Dimora Medical has launched the Dimora PHMB Skin and Wound Cleanser to address the challenges of chronic wound care, particularly for aging populations [1][15] - The cleanser effectively tackles biofilms, which complicate over 78% of chronic wounds, by breaking them down and killing 99.99% of bacteria within minutes [1][4][8] Product Features - The main ingredient, Polyhexamethylene Biguanide (PHMB), has demonstrated the ability to remove 99.49% of biofilm within three minutes and 99.99% after seven minutes [5] - The cleanser provides rapid antimicrobial action, killing 99.99% of bacteria in just two minutes for infected wounds and in one minute for non-infected wounds [8][9] - The product maintains its antimicrobial strength over time, achieving a 99.99% reduction in bacteria even after being opened for 28 days [12] Benefits for Caregivers - The cleanser simplifies the wound care process, allowing caregivers to clean and protect wounds quickly without multiple steps [9][15] - It reduces the risk of infection and complications, providing families with greater confidence in managing chronic wounds at home [6][16] - Dimora Medical aims to make home care easier and less stressful for families, positioning itself as a trusted expert in wound care [15][16]

As filed with the Securities and Exchange Commission on September 23, 2024 Registration No. 333-277731 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 9 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Cuprina Holdings (Cayman) Limited (Exact name of registrant as specified in its charter) Not Applicable (Translation of Registrant's name into English) (State or Other Jurisdiction of Incorporation or Organization) Cayman Islands 5047 Not Applicable (Pr ...

As filed with the Securities and Exchange Commission on June 20, 2024 Registration No. 333-277731 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Cuprina Holdings (Cayman) Limited (Exact name of registrant as specified in its charter) Not Applicable (Translation of Registrant's name into English) Cayman Islands 5047 Not Applicable (State or Other Jurisdiction of Incorporation or Organization) (Primary ...

As filed with the Securities and Exchange Commission on March 7, 2024 Washington, D.C. 20549 Registration No. FORM F-1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Cuprina Holdings (Cayman) Limited (Exact name of registrant as specified in its charter) Not Applicable (Translation of Registrant's name into English) Cayman Islands 5047 Not Applicable (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classific ...